Table 2. Comparison between actionable genes and the location of biliary tract cancer.
| Actionable gene | ICC
n = 66 |
ECC
n = 153 |
P-value | OR | 95% CI | ||
|---|---|---|---|---|---|---|---|
| Actionability (+) | 33 | (50) | 41 | (26.8) | 0.001 | 2.73 | (1.5–4.98) |
| ALK | 2 | (3) | 1 | (0.7) | 0.22 | 4.71 | (0.36–138.58) |
| ATM | 0 | (0) | 2 | (1.3) | 1 | 0 | (0–8.06) |
| BRAF | 3 | (4.5) | 3 | (2) | 0.37 | 2.37 | (0.42–13.44) |
| BRCA1 | 1 | (1.5) | 1 | (0.7) | 0.51 | 2.33 | (0.06–90.58) |
| BRCA2 | 3 | (4.5) | 0 | (0) | 0.03 | Inf | (1.38-Inf) |
| CDK4 | 3 | (4.5) | 1 | (0.7) | 0.08 | 7.17 | (0.78–188.1) |
| CDKN2A | 9 | (13.6) | 6 | (3.9) | 0.02 | 3.84 | (1.29–11.43) |
| EGFR | 0 | (0) | 2 | (1.3) | 1 | 0 | (0–8.06) |
| ERBB2 | 2 | (3) | 6 | (3.9) | 1 | 0.77 | (0.11–4.27) |
| FGFR1 | 2 | (3) | 2 | (1.3) | 0.59 | 2.35 | (0.25–22.13) |
| FGFR2 | 6 | (9.1) | 1 | (0.7) | 0 | 15.01 | (2.03–346.55) |
| FGFR3 | 1 | (1.5) | 3 | (2) | 1 | 0.77 | (0.03–7.12) |
| FLT3 | 2 | (3) | 0 | (0) | 0.09 | Inf | (0.67- Inf) |
| HRAS | 0 | (0) | 1 | (0.7) | 1 | 0 | (0–44.05) |
| IDH1 | 2 | (3) | 0 | (0) | 0.09 | Inf | (0.67-Inf) |
| KRAS | 6 | (9.1) | 8 | (5.2) | 0.37 | 1.81 | (0.59–5.63) |
| MDM2 | 5 | (7.6) | 4 | (2.6) | 0.13 | 3.04 | (0.79–12.35) |
| MET | 2 | (3) | 1 | (0.7) | 0.22 | 4.71 | (0.36–138.58) |
| NF1 | 2 | (3) | 6 | (3.9) | 1 | 0.77 | (0.11–4.27) |
| PIK3CA | 4 | (6.1) | 5 | (3.3) | 0.46 | 1.9 | (0.47–7.32) |
| PTEN | 8 | (12.1) | 8 | (5.2) | 0.09 | 2.49 | (0.88–7.05) |
| TSC1 | 0 | (0) | 1 | (0.7) | 1 | 0 | (0–44.05) |
Data are expressed as number (%). Statistical tests were performed using the chi-square test for the presence of Actionability and the Fisher test for each gene; P < 0.05 is considered statistically significant. Abbreviations: ICC: intrahepatic cholangiocarcinoma; ECC: extrahepatic cholangiocarcinoma; OR: odd ratio; CI: confidential interval.